Drug Profile
RBM 006
Alternative Names: RBM-006Latest Information Update: 15 Jul 2021
Price :
$50
*
At a glance
- Originator Ribomic
- Class Antifibrotics; Nucleotide aptamers; Skin disorder therapies
- Mechanism of Action ENPP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
- Discontinued Hepatic fibrosis; Scleroderma
Most Recent Events
- 15 Jul 2021 Preclinical development for Idiopathic pulmonary fibrosis is ongoing Japan (Parenteral) (Ribomic pipeline, July 2021)
- 15 Jul 2021 Discontinued - Preclinical for Hepatic fibrosis in Japan (Parenteral) (Ribomic pipeline, July 2021)
- 15 Jul 2021 Discontinued - Preclinical for Scleroderma in Japan (Parenteral) (Ribomic pipeline, July 2021)